Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	270.47B
Revenue (ttm)	91.34B
Net Income (ttm)	980.70M
Shares Out	1.33B
EPS (ttm)	0.73
PE Ratio	277.93
Forward PE	116.39
Dividend	0.14 (0.07%)
Ex-Dividend Date	Jul 16, 2025

Volume	3,129,930
Average Volume	3,796,582
Open	204.90
Previous Close	203.69
Day's Range	202.21 - 205.94
52-Week Range	181.73 - 307.90
Beta	0.06
RSI	61.18
Earnings Date	Oct 28, 2025

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 5,476
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In 2024, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.